Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer.
Lijuan LyuMeng WangYi ZhengTian TianYujiao DengPeng XuShuai LinSi YangLinghui ZhouQian HaoYing WuZhi-Jun DaiHuafeng KangPublished in: Cancer management and research (2020)
Our results suggest that FAM234B may be a candidate therapeutic target or prognostic marker for luminal breast cancer.